Oasmia Pharmaceutical’s AB CFO Michael af Winklerfelt has resigned from his role to take on new challenges outside the company. The process to recruit a successor has begun and is expected to be completed shortly. Michael af Winklerfelt will continue in his current role during the notice period of three months to ensure an orderly transition until a new CFO takes over.
“We thank Michael for his contributions to Oasmia and wish him the best in his new endeavours.” says Francois Martelet, CEO of Oasmia.
For more information:
Francois Martelet, Chief Executive Officer Oasmia
Phone: +46 18-50 54 40
About Oasmia Pharmaceutical
Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Oasmia produces novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on Oasmia’s proprietary technology platform XR17. Oasmia has been successful in moving its first product candidate, Apealea® (paclitaxel micellar), through clinical development, and has received market authorization in the European Union and other territories. Oasmia is in the process of transitioning into the commercialization phase of the product Apealea and making the product accessible to patients via its partnership with Elevar and its existing operations and partnerships in its retained territories. The company’s shares are traded on Nasdaq Stockholm (ticker: OASM). Visit www.vivesto.com for further information.